Interval between port catheter flushing can be extended to four months

Gynecologic and Obstetric Investigation

Volumn 70, Issue 2, 2010, Pages 91-94

  Ignatov, Atanas ^a   Ignatov, Tanja ^a   Taran, Andrei ^a   Smith, Bobbie ^a   Costa, Serban Dan ^a   Bischoff, Joachim ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Central vein access port; Flushing; Port maintenance; Totally implanted access port

Indexed keywords

ARTICLE; CANCER THERAPY; CATHETER; CENTRAL VENOUS CATHETERIZATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TOTALLY IMPLANTED ACCESS PORT; TREATMENT DURATION; UTERINE CERVIX CANCER;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 77956021160     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000294919     Document Type: Article

References (14)

1. Minassian VA, Sood AK, Lowe P, Sorosky JI, Al Jurf AS, Buller RE: Longterm central venous access in gynecologic cancer patients. J Am Coll Surg 2000; 191: 403-409.
2. Ignatov A, Hoffman O, Smith B, Fahlke J, Peters B, Bischoff J, Costa SD: An 11-year retrospective study of totally implanted central venous access ports: complications and patient satisfaction. Eur J Surg Oncol 2009; 35: 241-246.
3. Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E: Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 1982; 92: 706-712.
4. Randolph AG, Cook DJ, Gonzales CA, Andrew M: Benefit of heparin in central venous and pulmonary artery catheters: a metaanalysis of randomized controlled trials. Chest 1998; 113: 165-171.
5. Sitges-Serra A, Linares J, Garau J: Catheter sepsis: the clue is the hub. Surgery 1985; 97: 355-357.
6. Kuter DJ: Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9: 207-216.
7. Klerk CP, Smorenburg SM, Bueller HR: Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003; 163: 1913-1921.
8. Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S: Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 1995; 20: 108-111.
9. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP: Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168: 400-407.
10. Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP: The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014-1016.
11. Tenney JH, Moody, MR, Newman KA, Schimpff SC, Wade JC, Costerton, JW, Reed WP: Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer. Arch Intern Med 1986; 146: 1949-1954.
12. Mayo DJ, Cullinane AM, Merryman PK, Horne MK 3rd: Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices. Support Care Cancer 1998; 7: 425-427.
13. Kuo YS, Schwartz B, Santiago J, Anderson PS, Fields AL, Goldberg GL: How often should a port-A-cath be flushed? Cancer Invest 2005; 23: 582-585.
14. Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, Turhal NS: Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. Eur J Cancer Care 2009; 18: 191-194.